Perioperative prophylaxis with ertapenem reduced infections caused by extended-spectrum betalactamase-producing Enterobacteriaceae after kidney transplantation

Gemma Sanclemente 1, Marta Bodro 1*, Carlos Cervera 1, Laura Linares 1, Frederic Cofán 2, Francesc Marco 3, Jordi Bosch 3, Federico Oppenheimer 2, Fritz Dieckmann 2 and Asunción Moreno 1

Abstract

Background: In recent years we have witnessed an increase in infections due to multidrug-resistant organisms in kidney transplant recipients (KTR). In our setting, we have observed a dramatic increase in infections caused by extended-spectrum betalactamase-producing (ESBL) Enterobacteriaceae in KTR. In 2014 we changed surgical prophylaxis from Cefazolin 2 g to Ertapenem 1 g.

Methods: We compared bacterial infections and their resistance phenotype during the first post-transplant month with an historical cohort collected during 2013 that had received Cefazolin.

Results: During the study period 110 patients received prophylaxis with Cefazolin and 113 with Ertapenem. In the Ertapenem cohort we observed a non-statistically significant decrease in the percentage of early bacterial infection from 57 to 47%, with urine being the most frequent source in both. The frequency of infections caused by Enterobacteriaceae spp. decreased from 64% in the Cefazolin cohort to 36% in the Ertapenem cohort (p = 0.005). In addition, percentage of ESBL-producing strains decreased from 21 to 8% of all Enterobacteriaceae isolated (p = 0.015). After adjusted in multivariate Cox regression analysis, male sex (HR 0.16, 95% CI: 0.03–0.75), cefazolin prophylaxis (HR 4.7, 95% CI: 1.1–22.6) and acute rejection (HR 14.5, 95% CI: 1.3–162) were associated to ESBL-producing Enterobacteriaceae infection.

Conclusions: Perioperative antimicrobial prophylaxis with a single dose of Ertapenem in kidney transplant recipients reduced the incidence of early infections due to ESBL-producing Enterobacteriaceae without increasing the incidence of other multidrug-resistant microorganisms or C. difficile.

Keywords: Kidney transplantation, Infection, Surgical prophylaxis, Multidrug-resistant bacteria
Background
Infections are a major complication after kidney transplantation (KT). During the first post-transplant month, the majority of infections are caused by bacteria, most of them originating from the urine [1]. In recent years we have observed an increase in the incidence of infections caused by multidrug-resistant microorganisms, especially ESBL-producing Enterobacteriaceae [2]. These infections have been associated not only with increased costs, but also with higher mortality and graft loss [3, 4]. Perioperative prophylaxis is administered to prevent surgical site infections but, in the case of urological procedures, it also helps prevent postoperative bacteriuria. Classically guidelines recommend a single dose of Cefazolin in clean-contaminated surgical procedures, as is the case for kidney transplantation [5]. In our centre we have observed a high incidence of early infections caused by ESBL Enterobacteriaceae; the prevalence of infections caused by ESBL-producing Enterobacteriaceae in 2012 in kidney transplant recipients was 12%, mainly urinary tract infections (80%). For this reason, and based on the published data on the efficacy and safety of Ertapenem for surgical prophylaxis [6], we decided to change the antimicrobial prophylaxis for KT patients from Cefazolin 2 g to Ertapenem 1 g.

The aim of this study was to compare the incidence and susceptibility profile of bacterial infections in the first month after KT between patients who received Cefazolin and those who received Ertapenem.

Methods
We conducted an observational study at a tertiary university referral hospital with an active kidney transplantation programme (annual average of 120 procedures) in Barcelona, Spain. Until December 2013 all kidney transplant patients received a single dose of Cefazolin 2 g as perioperative antimicrobial prophylaxis. From January 2014 all patients undergoing KT received a single dose of Ertapenem 1 g. Although ertapenem requires a scaled dose adjustment in renal dysfunction in case of treatment, we do not consider adjustment because perioperative antimicrobial prophylaxis consists in a single dose of antibiotic. We collected data on all bacterial infections that occurred during the first post-transplant month, and compared patients who received a KT during 2013 (Cefazolin group, historical cohort) and patients undergoing KT during 2014 (Ertapenem group). Data was prospectively recorded from January to December 2014 and data from the historical cohort was collected retrospectively. Patients who received other perioperative antimicrobial prophylaxis were excluded. Cotrimoxazole was prescribed in all recipients for the prevention of Pneumocystis jirovecii pneumonia, given from the first day of oral tolerance until the sixth month post-transplantation. Double transplants were excluded. During the first month after transplantation follow-up was performed weekly. We routinely collect urine cultures after urinary catheter removal. Ureteral stents were only used in orthotopic transplantation (<5% of all procedures). Eighty-one kidney recipients received the monoclonal anti-IL2 receptor antagonist basiliximab therapy and 115 received rabbit anti-thymocyte globulin (ATG) as induction therapy. All patients received Corticosteroids and dose was progressively decreased from initially 1 mg/kg/day to 5 mg/day at 3 months post-transplantation. Mycophenolate mofetil (MMF) or sirolimus with tacrolimus or cyclosporine were maintenance immunosuppression.

Definitions
Urinary tract infection (UTI) was diagnosed based on the guidelines of the European Society of Clinical Microbiology and Infectious Disease Infectious Diseases Society of America [7, 8] and Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice [9]. Asymptomatic bacteriuria was defined when more than 100,000 UFC/mL of urinary pathogens were found in aseptically collected midstream urine in absence of symptomatology. Acute uncomplicated UTI (including cystitis and prostatitis) was defined when recipients presented urinary frequency/urgency, dysuria, suprapubic pain but no indwelling device and no systemic symptoms such as fever, allograft pain or hemodynamic compromise were present, and a urine culture yielding growth of more than 100,000 CFU/mL of urinary pathogens. Complicated UTI, including acute graft pyelonephritis or upper tract UTI, was defined as at least one of the following: malaise, chills, fever, hemodynamic instability, leukocytosis, pain over the allograft or the costovertebral angles for allograft or native kidney involvement, bacteremia with the same organism identified in urine culture and a significant growth of a uropathogen (≥10,000 CFU/mL).

Surgical site infection (SSI) was defined as those involving only skin and incisional subcutaneous tissue. Deep incisional SSI was present when involving deep tissues, including also infections draining through incision. Organ/Space SSI was considered if involving any part of the anatomy in organs and spaces manipulated during transplant surgery [10].

Venous catheter-related bloodstream infection was defined as the presence of bacteremia originating from an intravenous catheter when documenting a blood isolated cultured from the catheter tip using the Maki’s semiquantitative rollplate catheter culture (≥ 15 CFU). Primary or unknown source bacteremia was considered when a one or more blood cultures and organism cultured from blood was not related to an infection at another site.
Patients with septic shock can be identified by presenting a systolic pressure < 90 mmHg that was unresponsive to fluid therapy or required vasoactive drug treatment. All patients diagnosed of acute allograft rejection had biopsy. If kidney recipients required definitive hemodialysis, graft loss was considered.

We used Magiorakos et al. [11] criteria to defined multidrug resistance (MDR). Briefly, we considered Enterobacteriaceae and Pseudomonas aeruginosa to be MDR when a strain was resistant to one or more agent in three or more antimicrobial categories normally active against the isolated bacteria. For S. aureus, methicillin-resistant strains were considered MDR.

Microbiological studies
Matrix-Assisted Laser Desorption/Ionization Time of Flight (MALDI-TOF) technique was performed to identify microorganisms. Susceptibility testing of microorganisms recovered was done using the Phoenix automated system (Becton Dickinson Company, Sparks, Maryland), E-test or Kirby-Bauer disc-diffusion methods. To define susceptibility or resistance to antimicrobial agents we used the criteria of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) available at the time of diagnosis. Extended spectrum beta-lactamases (ESBLs) are defined as enzymes produced by certain bacteria that are able to hydrolyze extended spectrum cephalosporin and aztreonam (but not the cephamycins or carbapenems) and which are inhibited by β-lactamase inhibitors such as clavulanic acid [12]. EUCAST guidelines were followed in case of ESBL or a carbapenemase production suspicion [13, 14].

Statistical analysis
We used SPSS statistical package (version 18.0; SPSS, Chicago, Illinois, USA) to perform statistical analysis, using the χ² or Fischer exact test when comparing categorical variables and the Student t test or non-parametric tests depending on the homogeneity of the variable to compare continuous variables. We used Kaplan-Meier method to perform survival curves. We assessed the impact of age, sex, prior transplantation, prophylaxis group, reoperation, acute allograft rejection, diabetes mellitus and post transplant hemodialysis requirement on presenting infection caused by ESBL-producing Enterobacteriaceae using Cox proportional hazards regression model to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). All statistical tests were two-tailed, and the threshold of statistical significance was set at p < 0.05.

Results
During the study period, 110 patients received prophylaxis with Cefazolin and 113 with Ertapenem. We found no differences in the baseline pre-transplant variables, immunosuppression, non-infectious post-transplant complications or the incidence of early infection between cohorts (Table 1).

Outcomes are described in Table 2. Sixty-three patients in the Cefazolin group (57%) developed at least one episode of bacterial infection during the first month after transplantation compared to 53 patients (47%) in the Ertapenem group (p = 0.1). Ten patients of the Cefazolin group and 11 in the Ertapenem group presented two or more episodes of bacterial infection respectively. When we analysed only clinically significant infections (excluding asymptomatic bacteriuria from the analysis), the incidence was similar in both cohorts (26% in those who received Cefazolin and 20% in those who received Ertapenem, p = 0.2). Median days until urinary catheter removal were 9 (IQR 4–48).

If excluding asymptomatic bacteriuria, the timeline to the occurrence of a first infection after transplantation did not differ between groups (mean 10 days). The main source of infection was the urinary tract in both groups (85 and 70% in the Cefazolin and Ertapenem groups respectively, p = 0.09). Ten episodes (14%) in the Cefazolin group and eight (12%) in the Ertapenem group had positive blood cultures (p = 0.43). Regarding microbiology of bacteremic episodes, 28% were caused by P. aeruginosa, followed by E.coli (22%), K. pneumoniae (22%) and Staphylococci (11%). Regarding bacteremic episodes, the most important source of infection was urinary in the Cefazolin group (6 patients) and the venous catheter (4 patients) in the Ertapenem group respectively. Moreover, two episodes of bacteraemia in the Cefazolin group and none in the Ertapenem group were produced by MDR organisms. There was no difference between the two groups in terms of post-transplant complications, graft lost or mortality at 30 days.

Regarding infection foci, 34% of episodes of urinary tract infections were caused by E.coli, followed by Enterococcus spp. (34%), P. aeruginosa (7%) and K. pneumoniae (1%). Main aetiologies of SSI were Enterococcus spp. (34%), E.coli (33%) and S. aureus (22%).

We also performed a subanalysis of patients presenting with an ESBL-producing Enterobacteriaceae infection the first month after transplantation. All patients except 4 had urinary cultures within 2 months before transplantation (in case of residual diuresis). None of them had presented an infection caused by ESBL-producing Enterobacteriaceae prior transplantation.

We found no differences between groups regarding the incidence of infections caused by Pseudomonas aeruginosa (12% vs 14%, p = 0.9), Enterococcus spp. (33% vs 47%, p = 0.1), Candida spp. (9% vs 5%, p = 0.1) or Clostridium difficile (1% vs 2%, p = 1). E. faecium was isolated more frequently in the Cefazolin group (54%) than in the Ertapenem group (26%, p =
but none of the isolates were resistant to vancomycin. We did not detect any carbapenem-resistant Enterobacteriaceae. All episodes of Candida spp. infections were UTI. Only one episode of candidemia was diagnosed during the study period (in the group of ertapenem prophylaxis). Table 3 summarizes the characteristics of the infectious episodes.

Multivariate Cox regression analysis to evaluate risk for ESBL-producing Enterobacteriaceae infection among kidney recipients depending on some variables was performed in Table 4. According to HR figures, male sex (HR 0.16, 95% CI: 0.03–0.75), cefazolin prophylaxis (HR 4.7, 95% CI: 1.1–22.6) and acute allograft rejection (HR 14.5, 95% CI: 1.3–162) were associated to ESBL-producing Enterobacteriaceae infection. Nevertheless, age < 50 years (HR 0.5, 95% CI: 0.1–2.7), diabetes mellitus (HR 0.9, 95% CI: 1.6–5.7), post-transplant haemodialysis (HR 0.3, 95% CI: 0.06–1.2), nephrostomy requirement (HR 0.8, 95% CI: 1.3–0.1) and reoperation (HR 2.6, 95% CI: 0.6–12) could not be considered risk factors for ESBL-producing Enterobacteriaceae infection.

Regarding the aetiology of infectious episodes, we observed a significantly higher number of episodes caused by Enterobacteriaceae in the Cefazolin group (47 episodes, 64% of all isolates) than in the Ertapenem group (24 episodes, 36%) (p = 0.005). In addition, a higher percentage of isolates of Enterobacteriaceae were ESBL-producers in the Cefazolin group (10 episodes, 21%) comparing with the Ertapenem cohort (2 episodes, 8%, p = 0.01).

### Table 1 Clinical characteristics of the cohort according to prophylaxis received

| Variable                          | Cefazolin (n = 110) | Ertapenem (n = 113) | P   |
|----------------------------------|---------------------|---------------------|-----|
| Age in years (mean, ±SD)         | 54.02 (13.6)        | 53.99 (14.7)        | 1.0 |
| Male sex                         | 61 (55%)            | 65 (57%)            | 0.7 |
| Donor type                       |                     |                     |     |
| Deceased                         | 53 (48%)            | 61 (54%)            | 0.4 |
| Live                             | 57 (52%)            | 52 (46%)            |     |
| Donor's cause of death           |                     |                     |     |
| Anoxia                           | 14 (26%)            | 8 (15%)             | 0.1 |
| CVA                              | 31 (58%)            | 42 (80%)            |     |
| Trauma                           | 7 (13%)             | 2 (4%)              |     |
| Other                            | 1 (2%)              | 0                   |     |
| Median ischemia time (minutes, ±SD) | 473 (470) | 491 (434)          | 0.4 |
| Diabetes mellitus                | 24 (22%)            | 26 (23%)            | 0.8 |
| End-stage renal disease          |                     |                     |     |
| Glomerulonephritis               | 9 (8%)              | 6 (5%)              | 0.9 |
| Diabetes mellitus                | 17 (16%)            | 17 (16%)            |     |
| Hypertension                     | 19 (17%)            | 16 (14%)            |     |
| Cystic kidney disease            | 18 (16%)            | 17 (15%)            |     |
| Other Urologic                   | 8 (7%)              | 10 (9%)             |     |
| Other cause                      | 23 (21%)            | 23 (20%)            |     |
| Unknown/missing                  | 16 (15%)            | 24 (21%)            |     |
| Prior transplantation            | 18 (16%)            | 22 (19%)            | 0.6 |
| Immunosuppression regimen        |                     |                     |     |
| CNI + MMF + CS                   | 72 (65%)            | 64 (57%)            | 0.3 |
| CNI + mTOR + CS                  | 34 (31%)            | 46 (41%)            |     |
| Other                            | 4 (4%)              | 3 (2%)              |     |
| Induction                        |                     |                     |     |
| None                             | 18 (16%)            | 9 (8%)              | 0.4 |
| Basiliximab                      | 26 (24%)            | 55 (49%)            |     |
| Anti-lymphocyte globulines       | 66 (60%)            | 49 (43%)            |     |
| Pre-transplant rituximab         | 13 (12%)            | 13 (11%)            | 0.9 |

CVA Cerebrovascular accident, CNI Calcineurin inhibitors, MMF Mycophenolate mofetil, mTOR Inhibitors of mammalian target of rapamycin, CS Corticosteroids
The occurrence of ESBL-producing Enterobacteriaceae infections was not related to an active outbreak of nosocomial infection.

Figures 1 and 2 shows the Kaplan-Meier curves for probability of early infections and ESBL-producing Enterobacteriaceae infections respectively, by antibiotic prophylaxis received. Patients with Ertapenem prophylaxis presented fewer early infections (47%) than those with Cefazolin prophylaxis (57%) but not reaching statistical significance (log-rank, \( p = 0.1 \)). Patients with Ertapenem prophylaxis presented fewer infections caused by ESBL-producing Enterobacteriaceae (8%) than those with Cefazolin prophylaxis (21%) (log-rank, \( p = 0.01 \)).

None of the infections could be considered a donor-derived infection.

Graft loss at a 2-years follow-up was 4 and 7% between cefazolin and ertapenem group respectively (\( p = 0.2 \)). Mortality at a 2-years follow-up was 7 and 4% comparing cefazolin and ertapenem group respectively (\( p = 0.4 \)).

**Discussion**

In this large cohort of adult kidney transplant recipients, we found that perioperative antimicrobial prophylaxis with a single dose of Ertapenem reduced the incidence by almost half of Enterobacteriaceae infections and, more importantly, that the incidence of ESBL-producing strains decreased significantly by a third compared to the use of a single dose of Cefazolin in the first month post transplantation.

The main goal of perioperative prophylaxis is to reduce surgical site infections. According to the recent American guidelines on antimicrobial surgical prophylaxis, KTR should receive a single dose of Cefazolin 2g. However, a study performed during the 1990s found no differences in the incidence of early infection in KT patients who received perioperative prophylaxis and those who did not, suggesting that surgical prophylaxis can be avoided in KT patients [15]. More recently, some authors suggested using prophylaxis only in patients with a higher risk of surgical site infection, such as recipients older than 65 years or with a body mass index higher than 35 [16]. Regardless of all of these considerations, in our cohort of KT recipients the incidence of surgical site infection was 4%, and was not the main route of early infection. Instead, UTI were the most frequent type of infection, as in many previous studies [17, 18].

| Variable | Cefazolin (n=110) | Ertapenem (n=113) | \( P \) |
|----------|------------------|-------------------|--------|
| Post-transplant complications (first month) | | | |
| Acute rejection | 21 (19%) | 15 (13%) | 0.2 |
| Haemodialysis | 18 (16%) | 22 (20%) | 0.3 |
| Reoperation | 14 (13%) | 12 (11%) | 0.4 |
| Nephrostomy | 6 (5%) | 6 (5%) | 1 |
| Ureteral stent | 4 (4%) | 11 (10%) | 0.06 |
| Days of urinary catheter removal (mean, SD) | 9 (6) | 9 (6) | 0.8 |
| Patients with infection (first month) | 63 (57%) | 53 (47%) | 0.1 |
| Patients with clinically significant infection (first month)\(^a\) | 29 (26%) | 22 (20%) | 0.2 |
| Days until first infection (mean, SD) | 10 (7) | 11 (7) | 0.7 |
| Graft lost (30 days) | 0 | 2 (2%) | 1 |
| Mortality (30 days) | 0 | 1 (1%) | 0.9 |

\(^{a}\)Clinically significant infection: excluding asymptomatic bacteriuria

**Table 2** Outcomes of patients depending on perioperative antibiotic prophylaxis

**Table 3** Differences in clinical and microbiological characteristics of infectious episodes between the two cohorts

| Variable | Cefazolin (n=73) | Ertapenem (n=67) | \( P \) |
|----------|------------------|-------------------|--------|
| Source of infection | | | |
| Urinary | 62 (85%) | 47 (70%) | 0.09 |
| SSI | 3 (4%) | 6 (9%) | 0.5 |
| Other | 8 (11%) | 14 (21%) | 0.3 |
| Positive blood cultures | 10 (14%) | 8 (12%) | 0.4 |
| Septic shock | 2 (3%) | 1 (2%) | 0.6 |
| Isolated microorganisms | | | |
| Enterobacteriaceae | 47 (64%) | 24 (36%) | 0.005 |
| ESBL-producing | 10 (21%)\(^a\) | 2 (8%)\(^b\) | 0.01 |
| P. aeruginosa | 9 (12%) | 9 (14%) | 1 |
| XDR | 5 (36%) | 2 (22%) | 0.2 |
| Enterococcus spp. | 24 (33%) | 31 (47%) | 0.1 |
| E. faecium | 13 (54%) | 8 (26%) | 0.03 |
| C. difficile colitis | 1 (1%) | 2 (3%) | 1 |
| Candida spp. infection | 7 (9%) | 3 (5%) | 0.1 |
| CR Enterobacteriaceae | 0 | 0 | |

\(^{a}\)seven episodes were due to Klebsiella pneumoniae and three to E.coli

\(^{b}\)all episodes were due to Klebsiella pneumoniae

ESBL: Extended-spectrum β-lactamase-producing, XDR: Extensively drug-resistant, CR: Carbapenem-resistant
Interestingly, we observed a trend towards a lower incidence of infections during the first month post-transplantation using a single dose of Ertapenem, especially UTI. Furthermore, we observed a significant reduction in the incidence of infections due to *Enterobacteriaceae* and, more importantly, those strains producing ESBL. It is well known that ESBL-producing Gram-negative enteric bacilli infections after KT are associated with a worse prognosis for both the graft and patient and a high risk of UTI recurrence [4, 19]. Similar to our results, a Brazilian study described a reduction in the incidence of early UTI after KT when adding gentamycin to the usual prophylaxis [20]. However, the use of aminoglycosides in the early period after KT is not desirable due to its potential nephrotoxicity. In contrast, prolonging the duration of prophylaxis seems to have no impact on the occurrence of surgical site infection and UTI [21]. Moreover, Ertapenem is efficacious and safe for the prophylaxis of patients with abdominal surgery including colorectal manipulation [6, 22, 23]. Bora et al. [24] recommend tacrolimus concentration monitoring and

| Variable                      | ESLB-producing *Enterobacteriaceae* infection | HR (95%CI) | P  |
|-------------------------------|---------------------------------------------|------------|----|
|                               | Yes                                         | No         |    |
| Age                           |                                             |            |    |
| < 50 years                    | 2 (17%)                                     | 62 (60%)   | 0.5|
| ≥ 50 years                    | 10 (83%)                                    |            |    |
| Sex                           |                                             |            |    |
| Male                          | 2 (17%)                                     | 58 (56%)   | 0.16|
| Female                        | 10 (83%)                                    | 46 (44%)   |    |
| Diabetes mellitus             |                                             |            |    |
| Yes                           | 2 (17%)                                     | 80 (77%)   | 0.9|
| No                            | 10 (83%)                                    | 24 (23%)   |    |
| Prior transplantation         |                                             |            |    |
| Yes                           | 3 (25%)                                     | 86 (83%)   | 0.58|
| No                            | 9 (75%)                                     | 18 (17%)   |    |
| Prophylaxis group             |                                             |            |    |
| Cefazolin                     | 10 (83%)                                    | 53 (51%)   | 4.7|
| Ertapenem                     | 2 (17%)                                     | 51 (49%)   |    |
| Acute allograft rejection     |                                             |            |    |
| Yes                           | 1 (8%)                                      | 26 (25%)   | 14.5|
| No                            | 11 (92%)                                    | 78 (75%)   |    |
| Post-transplant Haemodialysis |                                             |            |    |
| Yes                           | 3 (25%)                                     | 26 (25%)   | 0.3|
| No                            | 9 (75%)                                     | 78 (75%)   |    |
| Nephrostomy                   |                                             |            |    |
| Yes                           | 1 (8%)                                      | 8 (8%)     | 0.8|
| No                            | 11 (92%)                                    | 96 (92%)   |    |
| Reoperation                   |                                             |            |    |
| Yes                           | 3 (25%)                                     | 11 (11%)   | 2.6|
| No                            | 9 (75%)                                     | 93 (89%)   |    |
dose reductions when the two drugs are administered in combination. Nevertheless perioperative prophylaxis consists in a single dose of ertapenem before surgery and patients usually start tacrolimus 24 h after surgery, so we think that adjustments may not be necessary. To the best of our knowledge, this is the first study analysing the efficacy of Ertapenem for the surgical prophylaxis of KT recipients.

Other variables associated with infections caused by ESBL-producing Enterobacteriaceae were prior transplantation, acute allograft rejection and female gender. It has been reported that the relative faecal abundance of ESBL E. coli is associated with UTI in women who have not been exposed to antibiotics [25]. Prior transplantation and acute allograft rejection may act as surrogate markers for other variables that might increase the probability of colonization by these organisms, such as antibiotic exposure and health care relationship, as others have found [26, 27], or even reflect a overimmunosuppression state that favors infection. Most studies agree that the Enterobacteriaceae causing UTI are ascending infections coming from the bowel after a previous colonization. In the setting of transplantation, Bert et al. found that pre-transplant faecal carriage of ESBL Enterobacteriaceae was an independent risk factor for infections caused by these organisms after liver transplantation [28], while a reduction in infections caused by Gram-negative bacteria was documented after selective bowel decontamination [29].
The main concern over administering broad-spectrum antibiotics is the development of infections caused by drug-resistant organisms. However, data about antimicrobial resistance in *Pseudomonas aeruginosa* infections showed a significant increase of antimicrobial resistance at 3 days of antibiotic administration [30, 31]. Likewise, we previously reported that one of the risk factors for infections with ESBL enteric bacilli in KT recipients was the prescription of antibiotics in addition to habitual prophylaxis [32]. Although Itani et al. reported a higher incidence of *C. difficile* infection in patients submitted to colorectal surgery who received prophylaxis with Ertapenem [6], we found no evidence of an increase in *C. difficile* infection, *P. aeruginosa* or carbapenem-resistant Enterobacteriaceae. A recent surveillance study also reported that the use of Ertapenem is not associated with an increase in drug-resistant Gram-negative bacilli [33].

A surprising result of our study was the decline in the occurrence of *E. faecium* infections in the Ertapenem cohort. It is well known that the activity of Ertapenem against *Enterococcus faecalis* is marginal and that *E. faecium* is resistant to all beta-lactams [34]. However, some years ago Mainardi et al. reported that imipenem could inhibit the synthesis of *E. faecium* peptidoglycan [35]. More recently, Dubée et al. reported this property for Ertapenem although its activity is lower than imipenem [36]. These studies analysed only the molecular basis of these interactions, but no study has evaluated its impact in the clinical setting. Nevertheless we hypothesize that the lower incidence of *E. faecium* and *P. aeruginosa* in the Ertapenem group were either random events or possibly due to an unknown factor not included in the analysis.

In recent years we have observed in our kidney transplant unit an increase in the incidence of infections caused by multidrug-resistant microorganisms, especially ESBL-producing Enterobacteriaceae and similar data has published in other centres worldwide [37–39]. Infections caused by multidrug-resistant pathogens caused an increasing number of healthcare-associated infections, causing a significant increment in costs and morbidity and mortality and are often associated with ICU admission and prior antibiotic use [40].

Reducing Enterobacteriaceae infections, especially ESBL-producing strains could mean reducing hospitalization and costs. However, in a long-term analysis, there was no statistical difference in 2-year graft loss neither 2-year mortality between the groups of prophylaxis. To avoid infection and especially colonization due to drug-resistant organisms some strategies have been described. First of all, shortening antibiotic regimens so as to decrease antibiotic-related selective pressures could be important prophylactic steps. Specifically, European guidelines recommend educational programmes based on hand hygiene, environmental cleaning, contact precautions and antimicrobial stewardship to reduce the horizontal spread of multidrug-resistant organisms during hospitalisation [41].

Our study had several limitations. First, as it was conducted in a single hospital ward, the results may not be applicable to other centres with different epidemiological backgrounds. Second, we did not perform a study of faecal carriage at the time of transplantation and, thus, we cannot rule out the possibility that the differences in the incidence of infections with Enterobacteriaceae between groups were due to different rates of pre-transplant bowel colonization. Furthermore, the combination of retrospective and prospective assessments limits the ability to truly compare the groups as it fails to consider the potential for local confounders in practices and epidemiologic changes. Moreover, we have no information about prior antibiotic exposure before transplantation. Although there were no changes in infection control protocol neither in surgical techniques or pre-transplant management during the study period, there could be potential pitfalls inherent in a comparison of two different eras. So, this data should be used to inform future more rigorous studies, including randomized ones.

**Conclusion**

In conclusion, a single perioperative prophylactic dose of Ertapenem in KT was effective at preventing surgical site infection and decreased the incidence of infections due to Enterobacteriaceae during the first post-transplant month, with a particular impact on ESBL-producing strains and *E. faecium*. The use of Ertapenem did not increase the incidence of other drug-resistant microorganisms as *P. aeruginosa*, *C. difficile*, *Candida* spp. or carbapenem-resistant Enterobacteriaceae.

**Abbreviations**

ESBL: Extended-spectrum beta-lactamase-producing; KT: Kidney transplantation; KTR: Kidney transplant recipients; MDR: Multidrug-resistant; UTI: Urinary tract infection

**Acknowledgements**

This work was supported by the “Red Española de Investigación en Patología Infecciosa” (REIPI, RD06/0008/1013).

**Authors’ contributions**

All authors participated in research design, in the writing of the paper, in the performance of the research and in data analysis. Moreover, they have been involved in drafting the manuscript and revising it and they have given the final approval of the version to be published. Finally, they also agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**Funding**

The authors have not received any funding for the conduct of this study.
Availability of data and materials
Clinical data were prospectively or retrospectively recorded depending on the time period and introduced into a database with coded names to maintain anonymity.

Ethics approval and consent to participate
The study was approved by our institution’s Ethics Committee. All patients signed an informed consent before undergoing kidney transplantation that agrees that their clinical data may be collected to research purposes.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Infectious Diseases, Hospital Clinic – IDIBAPS, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain. 2Kidney Transplant Unit, Hospital Clinic – IDIBAPS, University of Barcelona, Barcelona, Spain. 3Department of Microbiology, Centre Diagnòstic Biomèdic (CDB), Instituto de Salud Global de Barcelona (ISGlobal), Hospital Clinic – IDIBAPS, University of Barcelona, Barcelona, Spain.

Received: 15 March 2019 Accepted: 9 July 2019
Published online: 22 July 2019

References
1. Dorschner P, McElroy LM, Ison MG. Nosocomial infections within the first 3 months of solid organ transplantation. Transpl Infect Dis. 2014;16:171–87.
2. Cervera C, van Delden C, Galváld J, et al. ESCMID study group for infections in compromised hosts. Multidrug-resistant bacteria in solid organ transplant recipients. Clin Microbiol Infect. 2014;20(Suppl 7):49–73.
3. Evans HL, Lefrak SN, Lyman J, et al. Cost of gram-negative resistance. Crit Care Med. 2007;35(1):89–95.
4. Linares L, Cervera C, Cofán F, et al. Epidemiology and outcomes of multiple antibiotic-resistant bacterial infection in renal transplantation. Transpl Proc. 2007;39:2222.
5. Bitzler DW, Dellinger EP, Olsen KM, American Society of Health-System Pharmacists (ASHP), Infectious Diseases Society of America (IDSA), Surgical Infection Society (SIS), Society for Healthcare Epidemiology of America (SHEA), et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Surg Infect. 2013;14(1):73–156.
6. Itani KM, Wilson SE, Awad SS, et al. Ertapenem versus cefotetan prophylaxis in elective colorectal surgery. N Engl J Med. 2006;355(25):2640–51.
7. Hooston TM, Bradley SF, Cardenas DD, Infectious Diseases Society of America, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 international clinical practice guidelines from the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(5):625–65.
8. Gupta K, Hooston TM, Naber KG, Infectious Diseases Society of America, European Society for Microbiology and Infectious Diseases, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103–20.
9. Goldman JD, Julian K. Urinary tract infections in solid organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019:e13507. https://doi.org/10.1111/ctr.13507.
10. National Nosocomial Infections Surveillance (NNIS) report, data summary from October 1986–April 1996, issued May 1996. A report from the National Nosocomial Infections Surveillance (NNIS) System. Am J Infect Control. 1996;24(5):380–8.
11. Magorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–81.
12. Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: a clinical update. Clin Microbiol Rev. 2005;18:657–86.
13. European Committee on Antimicrobial susceptibility Testing Breakpoint tables for interpretation of MICs and zone diameters versions 1.0 to 4.0. http://www.eucast.org.
14. EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance. Version 1.0. http://www.eucast.org.
15. Midtvedt K, Hartmann A, Midtvedt T, Brekke JB. Routine perioperative antibiotic prophylaxis in renal transplantation. Nephrol Dial Transplant. 1998;13(7):1637–41.
16. Lafiavi MR, Rostami R, Patel S, et al. Universal perioperative antimicrobial prophylaxis is not necessary in kidney transplantation. Clin Transpl. 2012;64:37.
17. Souza RM, Oldburg J. Urinary tract infection in the renal transplant patient. Nat Clin Pract Nephrol. 2008;4(5):252–64.
18. Bodro M, Sanclemente G, Lipperheide I, et al. Impact of urinary tract infections on short-term kidney graft outcome. Clin Microbiol Infect. 2015;21(12):1104.e1–8.
19. Bodro M, Sanclemente G, Lipperheide I, et al. Impact of antibiotic resistance on the development of recurrent and relapsing symptomatic urinary tract infection in kidney recipients. Am J Transplant. 2015;15(4):1021–7.
20. Abbood CS, Bergamasco MD, Sousa EE, Zandonadi Ede C, Cortez D. Successful use of gentamicin as an antibiotic prophylaxis regimen to reduce the rate of healthcare-associated infections after renal transplantation. Braz J Infect Dis. 2013;17(2):234–5.
21. Orlando G, Manzia TM, Sorge R, et al. One-shot versus multidose perioperative antibiotic prophylaxis after kidney transplantation: a randomized, double-blind, controlled trial. Surgery. 2015;157(1):104–10.
22. Mahajan SN, Ariza-Heredia EJ, Rolston KV, et al. Perioperative antimicrobial prophylaxis for intra-abdominal surgery in patients with cancer: a retrospective study comparing ertapenem and nonertapenem antibiotics. Ann Surg Oncol. 2014;21(12):5139–9.
23. Leng XS, Zhao YJ, Qiu HZ, et al. Ertapenem prophylaxis of surgical site infections in elective colorectal surgery in China: a multicentre, randomized, double-blind, controlled study. J Antimicrob Chemother. 2014;69(12):3379–86.
24. Bora F, Aliosmanoglou I, Kocak H, Dinckan A, Uslu HB, Gunseren F, Suleymanlar G. Drug interaction between tacrolimus and ertapenem in renal transplantation recipients. Transplant Proc. 2012;44(10):3029–32.
25. Ruppe E, Ioanidu B, Cojocaru R, et al. Relative fecal abundance of extended-spectrumβ-lactamase-producing Escherichia coli strains and their occurrence in urinary tract infections in women. Antimicrob Agents Chemother. 2013;57(9):4512–7.
26. Rodríguez-Bano J, Picon E, Gijon P, Hernandez JR, Mellado JM, Pena C, et al. Risk factors and prognosis of nosocomial bloodstream infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli. J Clin Microbiol. 2010;48(5):1726–31.
27. Linares L, Garcia-Goez JF, Cervera C, Almela M, Sanclemente G, Cofán F, et al. Early bacteremia after solid organ transplantation. Transplant Proc. 2009;41(6):2262–4.
28. Bert F, Larroque B, Paugam-Burtz C, et al. Pretransplant fecal carriage of extended-spectrum-β-lactamase-producing Enterobacteriaceae and infection after liver transplantation. France. Emerg Infect Dis. 2012;18(6):908–16.
29. Safdar N, Said A, Lucey MR. The role of selective digestive decontamination for reducing infection in patients undergoing liver transplantation: a systematic review and meta-analysis. Liver Transpl. 2004;10(7):817–27.
30. Boyer A, Doussau A, Thébault R, et al. Pseudomonas aeruginosa acquisition on an intensive care unit: relationship between antibiotic selective pressure and patients’ environment. Crit Care. 2011;15(1):R55.
31. Cobos-Trigueros N, Solé M, Castro P, et al. Acquisition of Pseudomonas aeruginosa and its resistance phenotypes in critically-ill medical patients: role of colonization pressure and antibiotic exposure. Crit Care. 2015;19(1):218.
32. Linares L, Cervera C, Cofán F, et al. Risk factors for infection with extended-spectrum and AmpC beta-lactamase-producing gram-negative rods in renal transplantation. Am J Transplant. 2008;8(S):1000–5.
33. Rodriguez-Osorio CA, Sanchez-Martinez CO, Araujo-Melendez J, et al. Impact of ertapenem on antimicrobial resistance in a sentinel group of gram-negative bacilli: a 6 year antimicrobial resistance surveillance study. J Antimicrob Chemother. 2015;70(3):914–21.
34. Livermore DM, Sefton AM, Scott GM. Properties and potential of ertapenem. J Antimicrob Chemother. 2003;52(3):331–44.
35. Mainardi JL, Hugonnet JE, Rusconi F, et al. Unexpected inhibition of peptidoglycan LD-transpeptidase from Enterococcus faecium by the beta-lactam imipenem. J Biol Chem. 2007;282(42):30414–22.

36. Dubée V, Arthur M, Fief H, et al. Kinetic analysis of Enterococcus faecium LD-transpeptidase inactivation by carbapenems. Antimicrob Agents Chemother. 2012;56(6):3409–12.

37. Espinar MJ, Miranda IM, Costa-de-Oliveira S, et al. Urinary tract infections in kidney transplant patients due to Escherichia coli and Klebsiella pneumoniae-producing extended-Spectrum β-lactamases: risk factors and molecular epidemiology. PLoS One. 2015;10(8):e0134737.

38. Korth J, Kukalla J, Rath PM, et al. Increased resistance of gram-negative urinary pathogens after kidney transplantation. BMC Nephrol. 2017;18(1):164.

39. Kritikos A, Manuel O. Bloodstream infections after solid-organ transplantation. Virulence. 2016;7(3):329–40.

40. Bodro M, Sabé N, Tubau F, Lladó L, Baliellas C, Roca J, Cruzado JM, Camarà J. Risk factors and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens in solid-organ transplant recipients. Transplantation. 2013;96(9):843–9.

41. Tacconelli E, Cataldo MA, Dancer SJ, et al. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant gram-negative bacteria in hospitalized patients. Clin Microbiol Infect. 2014;20(Suppl 1):1–55.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.